UA126582C2 - Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду - Google Patents
Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду Download PDFInfo
- Publication number
- UA126582C2 UA126582C2 UAA202000506A UAA202000506A UA126582C2 UA 126582 C2 UA126582 C2 UA 126582C2 UA A202000506 A UAA202000506 A UA A202000506A UA A202000506 A UAA202000506 A UA A202000506A UA 126582 C2 UA126582 C2 UA 126582C2
- Authority
- UA
- Ukraine
- Prior art keywords
- crystalline form
- compound
- disorders
- peaks
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 | ||
| PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA126582C2 true UA126582C2 (uk) | 2022-11-02 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202000506A UA126582C2 (uk) | 2017-07-05 | 2018-07-04 | Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (enExample) |
| EP (1) | EP3649117B1 (enExample) |
| JP (2) | JP2020525475A (enExample) |
| KR (1) | KR102645911B1 (enExample) |
| CN (1) | CN110831932A (enExample) |
| AU (1) | AU2018296423B2 (enExample) |
| BR (1) | BR112020000099A2 (enExample) |
| CA (1) | CA3067489A1 (enExample) |
| CL (1) | CL2020000002A1 (enExample) |
| EA (1) | EA202090193A1 (enExample) |
| IL (1) | IL271764B2 (enExample) |
| MA (1) | MA50972A (enExample) |
| MY (1) | MY206357A (enExample) |
| PH (1) | PH12020500040A1 (enExample) |
| SG (1) | SG11201912881SA (enExample) |
| UA (1) | UA126582C2 (enExample) |
| WO (1) | WO2019008034A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
| US20230047102A1 (en) | 2019-12-20 | 2023-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| CN118202050A (zh) * | 2021-08-17 | 2024-06-14 | 韩国科学技术院 | 靶向cav3.1基因的反义寡核苷酸及其用途 |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| JP6500092B2 (ja) | 2014-09-15 | 2019-04-10 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物 |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
-
2018
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active Active
- 2018-07-04 EP EP18749304.4A patent/EP3649117B1/en active Active
- 2018-07-04 MY MYPI2020000011A patent/MY206357A/en unknown
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en not_active Ceased
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11555025B2 (en) | 2023-01-17 |
| BR112020000099A2 (pt) | 2020-07-07 |
| WO2019008034A1 (en) | 2019-01-10 |
| SG11201912881SA (en) | 2020-01-30 |
| EA202090193A1 (ru) | 2020-06-03 |
| JP2023123679A (ja) | 2023-09-05 |
| MA50972A (fr) | 2020-10-14 |
| US20200165221A1 (en) | 2020-05-28 |
| US11059803B2 (en) | 2021-07-13 |
| MY206357A (en) | 2024-12-12 |
| JP2020525475A (ja) | 2020-08-27 |
| CN110831932A (zh) | 2020-02-21 |
| IL271764B1 (en) | 2023-06-01 |
| IL271764A (en) | 2020-02-27 |
| EP3649117B1 (en) | 2024-10-09 |
| CA3067489A1 (en) | 2019-01-10 |
| KR102645911B1 (ko) | 2024-03-08 |
| CL2020000002A1 (es) | 2020-07-31 |
| US20210300894A1 (en) | 2021-09-30 |
| KR20200018698A (ko) | 2020-02-19 |
| PH12020500040A1 (en) | 2020-10-12 |
| IL271764B2 (en) | 2023-10-01 |
| AU2018296423A1 (en) | 2020-02-20 |
| AU2018296423B2 (en) | 2022-07-28 |
| EP3649117A1 (en) | 2020-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA126582C2 (uk) | Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду | |
| CA2865585C (en) | N-(5s, 6s, 9r)-5-amino-6-(2,3-difluorophenyl)-6, 7, 8, 9-tetrahydro-5h-cyclohepta [b] pyridin-9-yl-4-(2-oxo-2, 3-dihydro-1h-imidazo [4, 5-b] pyridin-1-yl) piperidine-1-carboxylate, hemisulfate salt | |
| EP2276758B1 (en) | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol | |
| EP3456722B1 (en) | Crystal forms of crisaborole in free form and preparation method and use thereof | |
| BR112019021447A2 (pt) | sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica | |
| US20210002307A1 (en) | Crystal Forms of Crisaborole In Free Form And Preparation Method And Use Thereof | |
| KR20130136544A (ko) | 아고멜라틴의 신규한 결정성 형태 vii, 및 이의 제조 방법 및 용도 및 이를 함유하는 약학적 조성물 | |
| CN111094272B (zh) | 一种otr抑制剂的可药用盐、晶型及制备方法 | |
| CN108794383B (zh) | 硝苯地平与异烟酰胺的共晶 | |
| WO2024051771A1 (zh) | 一种五元并六元杂环化合物的晶型及其制备方法和应用 | |
| CN111094273B (zh) | 催产素受体抑制剂的晶型及其制备方法 | |
| TWI711612B (zh) | 氮雜雙環基取代的三唑類衍生物的可藥用鹽、晶型及製備方法 | |
| CN108484470B (zh) | 一种奥拉西坦的制备方法 | |
| CN119306783A (zh) | 一种甾体类化合物的晶型及其用途 | |
| TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 |